Among these, sunitinib [48] is a multi-target receptor tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), etc. It is often used as a chemotherapeutic agent to treat renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors. Here, KDR is linked to renal cell carcinoma.